Relypsa Offers Data Published in New England Journal of Medicine for Pivotal Phase 3 Program of Patiromer FOS
November 21, 2014 at 12:01 PM EST
Relypsa, Inc. (Nasdaq: RLYP), a biopharmaceutical company, announced that results from the pivotal Phase 3 program of the company's ...